Evidence map›Paper›PMID 33539524›Full record

ArticleJournal of public health (Oxford, England)2022

Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictor.

Janet Lin, Cammeo Mauntel-Medici, Anjana Bairavi Maheswaran, Sara Baghikar, Oksana Pugach, Ellen M Stein, Michelle T Martin, Hai Nguyen

Open access · hybridAbstract read
In one paragraph

Article in Journal of public health (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Hepatitis C Cascades: Data to Inform Hepatitis C Elimination in the United States.Public health reports (Washington, D.C. : 1974) · 2023
    Review
  3. Health Insurance and Initiation of Direct-Acting Antivirals for Hepatitis C in US Women With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Janet LinDepartment of Emergency Medicine, College of Medicine, University of Illinois at Chicago, 808 S. Wood Street, Chicago, IL 60612, USA.ORCID 0000-0002-4347-5060
Cammeo Mauntel-MediciDepartment of Emergency Medicine, College of Medicine, University of Illinois at Chicago, 808 S. Wood Street, Chicago, IL 60612, USA.
Anjana Bairavi MaheswaranDepartment of Emergency Medicine, College of Medicine, University of Illinois at Chicago, 808 S. Wood Street, Chicago, IL 60612, USA.ORCID 0000-0002-1720-0282
Sara BaghikarDepartment of Emergency Medicine, College of Medicine, University of Illinois at Chicago, 808 S. Wood Street, Chicago, IL 60612, USA.
Oksana PugachInstitute for Health Research and Policy, University of Illinois at Chicago, 1747 W. Roosevelt Road, Chicago, IL 60608, USA.
Ellen M SteinDepartment of Emergency Medicine, College of Medicine, University of Illinois at Chicago, 808 S. Wood Street, Chicago, IL 60612, USA.
Michelle T MartinDepartment of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612, USA.
Hai NguyenInstitute for Health Research and Policy, University of Illinois at Chicago, 1747 W. Roosevelt Road, Chicago, IL 60608, USA.
University of Illinois Chicago · USRoosevelt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic hepatitis C (HCV) infection affects over 2.4 million Americans and accounts for 18 000 deaths per year. Treatment initiation in this population continues to be low even after introduction of highly effective and shorter duration direct-acting antivirals. This study assesses factors that influence key milestones in the HCV care continuum.

methodsRetrospective time-to-event analyses were performed to assess factors influencing liver fibrosis staging and treatment initiation among individuals confirmed with chronic HCV infection at University of Illinois Hospital and Health Sciences System between 1 August 2015 and 24 October 2016 and followed through 28 January 2018. Cox regression models were utilized for multivariable analyses.

resultsIndividuals tested at the liver clinic (hazard ratio [HR] = 2.03; 95% confidence interval [CI]: 1.19-3.46) and at the federally qualified health center (HR = 3.51; 95% CI: 2.19-5.64) had higher instantaneous probability of being staged compared with individuals tested at the emergency department (ED) or inpatient setting. And probability of treatment initiation increased with advancing liver fibrosis especially for Medicaid beneficiaries (HR = 1.64; 95% CI: 1.35-1.99).

conclusionsThe study demonstrates a need for improving access for patients with early stages of the disease in order to reduce HCV-related morbidity and mortality, especially those tested at nontraditional care locations such as the ED or the inpatient setting.

Indexed as

Hepatitis CHepatitis C, ChronicInsuranceAntiviral AgentsHumansLiver CirrhosisRetrospective StudiesUnited StatesAntiviral Agentschronic diseasemanagement and policy

Identifiers

PMID33539524
PMCPMC8904194
OpenAlexW3126471594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.